Literature DB >> 11889232

Analysis of antibody gene rearrangement, usage, and specificity in chronic focal encephalitis.

S E Baranzini1, K Laxer, R Saketkhoo, M K Elkins, J M Parent, R Mantegazza, J R Oksenberg.   

Abstract

BACKGROUND: Autoantibodies have been implicated in the development of chronic focal encephalitis (CFE) or Rasmussen's disease, a progressive and intractable form of epilepsy characterized by uncontrollable unilateral focal seizures, brain atrophy, and inflammation.
OBJECTIVE: To investigate the origin and characteristics of the B cell population that trigger or sustain brain inflammation in patients with CFE.
METHODS: The authors used immunoglobulin (Ig) complementary determining region 3 (CDR3)-size spectratyping and DNA sequencing to examine the rearranged IgG heavy chain (IgGH) transcript repertoire in resected brain samples from four patients with CFE. They also performed Western blotting on human and rat brain homogenates and immunostaining on a human neuronal cell line to test the reactivity of sera from patients with CFE.
RESULTS: The authors observed substantial perturbations from the normal, unstimulated repertoire of immunoglobulin genes. Sequencing of randomly selected clones confirmed the restricted profile and provided evidence for somatic mutation patterns characteristic of antigen-specific stimulation. They also observed IgGVH-CDR3 sequence diversity among patients. When sera were assayed from patients with CFE for specificity against rat and human brain homogenates, heterogeneous reactivity patterns were detected among patients. Immunostaining of postmitotic human neuronal cells demonstrated reactivity of some patients' sera against neural antigens.
CONCLUSIONS: These findings support an important role for clonally expanded B lymphocytes in some forms of epilepsy, but also indicate a wide spectrum of reactivity characteristic of antigenic heterogeneity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11889232     DOI: 10.1212/wnl.58.5.709

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  5 in total

1.  Scavenging reactive oxygen species inhibits status epilepticus-induced neuroinflammation.

Authors:  Pallavi B McElroy; Li-Ping Liang; Brian J Day; Manisha Patel
Journal:  Exp Neurol       Date:  2017-08-16       Impact factor: 5.330

Review 2.  Seizures and risk of epilepsy in autoimmune and other inflammatory encephalitis.

Authors:  Marianna Spatola; Josep Dalmau
Journal:  Curr Opin Neurol       Date:  2017-06       Impact factor: 5.710

Review 3.  Glutamate receptor antibodies in neurological diseases: anti-AMPA-GluR3 antibodies, anti-NMDA-NR1 antibodies, anti-NMDA-NR2A/B antibodies, anti-mGluR1 antibodies or anti-mGluR5 antibodies are present in subpopulations of patients with either: epilepsy, encephalitis, cerebellar ataxia, systemic lupus erythematosus (SLE) and neuropsychiatric SLE, Sjogren's syndrome, schizophrenia, mania or stroke. These autoimmune anti-glutamate receptor antibodies can bind neurons in few brain regions, activate glutamate receptors, decrease glutamate receptor's expression, impair glutamate-induced signaling and function, activate blood brain barrier endothelial cells, kill neurons, damage the brain, induce behavioral/psychiatric/cognitive abnormalities and ataxia in animal models, and can be removed or silenced in some patients by immunotherapy.

Authors:  Mia Levite
Journal:  J Neural Transm (Vienna)       Date:  2014-08-01       Impact factor: 3.575

4.  A case of Rasmussen encephalitis treated with rituximab.

Authors:  Barbara Thilo; Robert Stingele; Karina Knudsen; Rainer Boor; Christian G Bien; Günther Deuschl; Nicolas Lang
Journal:  Nat Rev Neurol       Date:  2009-08       Impact factor: 42.937

5.  Shared HLA Class I and II Alleles and Clonally Restricted Public and Private Brain-Infiltrating αβ T Cells in a Cohort of Rasmussen Encephalitis Surgery Patients.

Authors:  Sugandha Dandekar; Hemani Wijesuriya; Tim Geiger; David Hamm; Gary W Mathern; Geoffrey C Owens
Journal:  Front Immunol       Date:  2016-12-19       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.